Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pipex Pharmaceuticals, which develops late-stage drug candidates for the treatment of central nervous system and autoimmune diseases, has appointed Nicholas Stergis as its new CEO.
Subscribe to our email newsletter
Mr Stergis replaces Steve Kanzer who will continue to serve as Pipex’s chairman. Daniel Dorman, a director of the company, has resigned and Charles Bisgaier, Pipex’s president, has resigned from the company to establish a Michigan-based venture capital group focused on the life sciences sector.
Mr Stergis was co-founder of Pipex Therapeutics, the predecessor company, and has been vice chairman of Pipex’s board of directors since March 2007.
Mr Kanzer said: “I feel confident in Nicholas’s operational strengths, business acumen, business development capabilities and look forward to his service as CEO to create substantial value for our shareholders.”